<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04422457</url>
  </required_header>
  <id_info>
    <org_study_id>2020KT62</org_study_id>
    <nct_id>NCT04422457</nct_id>
  </id_info>
  <brief_title>Specific Molecular Imaging of DX600 Labeled by PET Radionuclide Targeting ACE2 in Patients</brief_title>
  <official_title>Specific Molecular Imaging of DX600 Labeled by PET Radionuclide Targeting ACE2 in Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Angiotensin-converting enzyme 2 (ACE2) plays an important role in renin-angiotensin system
      (RAS) and has been reported to relate with cancer. Recently, it has also been proved as the
      key target for COVID-19 infection.

      DX600 is a polypeptide that can specific binding to ACE2 specifically with nanomolar affinity
      reported in literature. This study constrcuted a radio-tracer, DX600 Labeled by PET
      Radionuclide, to monitoring biodistribution ACE2 in human beings, evaluate the detection
      ability of radio-tracer in ACE2 over-expression tumors and dynamic changes of ACE2 expression
      under therapy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SUV</measure>
    <time_frame>2 years</time_frame>
    <description>The uptake of uptake of the tracer in the primary and metastatic tumor lesions by measuring standardized uptake value（SUV）</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Imaging cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All study participants will be allocated to this arm (single-arm study).Study participants will undergo 68Ga-DX600 PET/CT scans</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>68Ga-DX600 PET/CT</intervention_name>
    <description>DX600, labeled with 68Ga will be used as a molecular imaging tracer for PET/CT scanning</description>
    <arm_group_label>Imaging cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-75 years old; both sex;

          -  ECoG 0 or 1;

          -  Patients that would undergo biopsy or surgical operation with high ACE2 expression
             tumors such as colorectal cancer, renal cancer, pancreatic cancer, gastric cancer,
             liver cancer, lung cancer, brain cancer or suspected tumor.

          -  use 18F-FDG PET/CT as baseline evaluation

        Exclusion Criteria:

          -  Significant hepatic or renal dysfunction;

          -  Is Pregnant or ready to pregnant;

          -  Cannot lie on their back for half an hour;

          -  Suffering from claustrophobia or other mental diseases;

          -  Refusal to join the clinical study;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hua Zhu</last_name>
    <phone>010-88196495</phone>
    <email>zhuhuabch@pku.edu.cn</email>
  </overall_contact>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 5, 2020</study_first_submitted>
  <study_first_submitted_qc>June 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>June 5, 2020</last_update_submitted>
  <last_update_submitted_qc>June 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Hua Zhu</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

